Empirical Asset Management LLC Takes $1.15 Million Position in Kenvue Inc. (NYSE:KVUE)

Empirical Asset Management LLC acquired a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 53,636 shares of the company's stock, valued at approximately $1,145,000.

Other large investors also recently made changes to their positions in the company. Beech Hill Advisors Inc. lifted its holdings in shares of Kenvue by 0.9% in the 4th quarter. Beech Hill Advisors Inc. now owns 106,881 shares of the company's stock worth $2,282,000 after purchasing an additional 987 shares in the last quarter. StrongBox Wealth LLC boosted its position in shares of Kenvue by 8.0% during the fourth quarter. StrongBox Wealth LLC now owns 82,057 shares of the company's stock valued at $1,752,000 after buying an additional 6,085 shares during the last quarter. Essex Savings Bank grew its holdings in Kenvue by 4.0% during the fourth quarter. Essex Savings Bank now owns 17,409 shares of the company's stock worth $372,000 after buying an additional 665 shares in the last quarter. Wolff Wiese Magana LLC lifted its stake in Kenvue by 2.0% during the 4th quarter. Wolff Wiese Magana LLC now owns 78,513 shares of the company's stock valued at $1,676,000 after acquiring an additional 1,514 shares in the last quarter. Finally, Park Avenue Securities LLC boosted its holdings in Kenvue by 860.2% during the 4th quarter. Park Avenue Securities LLC now owns 232,282 shares of the company's stock worth $4,959,000 after acquiring an additional 208,092 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

KVUE stock traded down $0.09 during mid-day trading on Friday, reaching $21.11. 11,266,973 shares of the company traded hands, compared to its average volume of 8,612,558. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a market capitalization of $40.46 billion, a P/E ratio of 38.37, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a fifty day moving average price of $22.42 and a 200-day moving average price of $21.66.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same quarter last year, the company earned $0.31 earnings per share. The firm's quarterly revenue was down .4% on a year-over-year basis. As a group, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.89%. The ex-dividend date is Wednesday, February 12th. Kenvue's payout ratio is 149.09%.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Royal Bank of Canada upgraded shares of Kenvue from a "hold" rating to a "moderate buy" rating in a report on Monday, December 9th. Jefferies Financial Group initiated coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a "buy" rating and a $27.00 price objective for the company. Barclays cut their target price on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Friday. Citigroup reduced their price target on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating for the company in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and dropped their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.